Free Trial
OTCMKTS:USRM

U.S. Stem Cell (USRM) Stock Price, News & Analysis

U.S. Stem Cell logo

About U.S. Stem Cell Stock (OTCMKTS:USRM)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
304,689 shs
Market Capitalization
$66,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Receive USRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

USRM Stock News Headlines

2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
See More Headlines

USRM Stock Analysis - Frequently Asked Questions

U.S. Stem Cell, Inc. (OTCMKTS:USRM) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The company had revenue of $1.30 million for the quarter.

Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that U.S. Stem Cell investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Auxly Cannabis Group (CBWTF), EVgo (EVGO), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX).

Company Calendar

Last Earnings
8/07/2019
Today
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
OTCMKTS:USRM
Previous Symbol
NASDAQ:BHRT
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
550,903,000
Market Cap
$66,000.00
Optionable
Not Optionable
Beta
-1.29

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (OTCMKTS:USRM) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners